Location: Newton, MA

Lumicell Awarded Direct Phase II Small Business Innovation Research (SBIR) Grant from the National Cancer Institute to Conduct Multi-Center Pivotal Study

Funding will Support Trial of the Lumicell Margin Assessment System (MAS) in Breast Cancer Surgery Wellesley, Mass., August 9, 2016 – Lumicell, a leader in the field of image-guided surgery, today announced that the National Cancer Institute (NCI) has awarded the Company a Phase II Small Business Innovation Research (SBIR) grant to fund a prospective multi-center pivotal study of the Lumicell Margin Assessment System (MAS) in breast cancer surgery. The company aims to demonstrate tha...
Read More

Lumicell Successfully Completes Phase 2a Feasibility Study

Revolutionary Approach to Imaging Tumor Cells Achieved 100% Detection of Residual Cancer and Well Tolerated in First Patient Samples Poster Presentation of Trial Findings at The American Society of Breast Surgeons Annual Meeting Wellesley, Mass., April 13, 2016 – Lumicell, a leader in the field of image-guided cancer surgery, today announced it successfully completed its Phase 2a feasibility study on the Company’s groundbreaking LUM Imaging System, consisting of an optical contrast...
Read More

Lumicell Publishes Data Supporting LUM015, Fluorescent Probe for Imaging Cancer, in Science Translational Medicine

Revolutionary Approach to Imaging Tumor Cells Demonstrated to be Well Tolerated in First Patient Samples Wellesley, Mass., January 6, 2016 – Lumicell, a leader in the field of image-guided cancer surgery, today announced the publication of research supporting the Company’s groundbreaking protease-activated fluorescent imaging probe, LUM015, in Science Translational Medicine. The research highlights the use of LUM015 to detect cancer in vivo in a mouse model of soft tissue...
Read More

Lumicell Announces FDA Approval to Launch Feasibility Study in Gastrointestinal Cancers

Trial is funded by National Cancer Institute’s SPORE program Wellesley, Mass., September 10, 2015 – Lumicell, a leader in the field of image-guided cancer surgery, has received approval from the U.S. Food and Drug Administration (FDA) to launch a feasibility (pilot) study in gastrointestinal cancers. The study will focus on imaging tissue in patients with esophageal, colorectal and pancreatic cancers. The study will be conducted at Massachusetts General Hospital (MGH) and will be led by...
Read More

Lumicell Announces FDA Approval to Launch Feasibility Study

Trial is funded by National Cancer Institute grant Wellesley, Mass., May 20, 2015 – Lumicell, a leader in the field of image-guided cancer surgery, has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to launch a feasibility (pilot) study for intraoperative imaging of breast cancer during surgery. The study will be conducted at Massachusetts General Hospital (MGH). Further trial information can be found here: https://clinicaltr...
Read More

Lumicell Phase 1 Results Presented at SSO 2015 Annual Cancer Symposium

Phase 1 Results Also Presented at AACR 2015 Annual Meeting Wellesley, Mass., May 8, 2015 – Lumicell, a leader in the field of image-guided cancer surgery, announced that Phase 1 trial results were recently presented at the SSO 2015 Annual Cancer Symposium in March and the AACR 2015 Annual Meeting in April. Both sessions were presented by Lumicell’s clinical collaborators at Duke University Medical Center. Lumicell recently completed its Phase 1 safety study at Duke University...
Read More
en_USEnglish